Compare ADMA Biologics Inc (ADMA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Orion Office REIT Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Orion Office REIT Inc trades at $2.78 (market cap $157.99M). The key difference: ADMA Biologics Inc is far larger — about 13.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.88% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ONL | |
|---|---|---|
Market Cap | $2.13B | $157.99M |
Sector | Health | Real Estate |
52-Week High | $20.38 | $3.04 |
52-Week Low | $7.60 | $1.93 |
Enterprise Value | $2.20B | $641.64M |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ONL trades at $2.78, down 1.77% on the day, with a neutral technical signal and bearish moving averages. The company shows a gross margin of 56.71% but deep net losses, with revenue declining from $208M in 2022 to $148M in 2025. Recent news highlights progress on leasing and strategic reviews, while cash flow remains positive but shrinking.
Outlook is cautious due to persistent losses and high debt, though strategic asset sales and refinancing reduce near-term risks. The 50% analyst buy rating offers some optimism, but investors face significant fundamental challenges amid the troubled office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
